PART I . Overview We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization. In December 2024, we entered into an intell...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104158 | EDGAR | 110K words |
| 2025-03-28 | 2024-12-31 | 0001628280-25-015269 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001628280-24-010901 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0001628280-23-009583 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010721 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012252 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011174 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006602 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001564590-18-005868 | EDGAR | — |
| 2017-03-07 | 2016-12-31 | 0001213900-17-002066 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268895 | EDGAR | 81K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105081 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001628280-25-023932 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001628280-24-045698 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035636 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021657 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037905 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001628280-23-028562 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001628280-23-017234 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029228 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001628280-22-022208 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019856 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-103117 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-268134 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104592 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140810 | EDGAR | — |
| 2025-05-08 | 0001628280-25-023788 | EDGAR | — |
| 2025-03-26 | 0001193125-25-063253 | EDGAR | — |
| 2025-03-18 | 0001193125-25-056708 | EDGAR | — |
| 2025-03-04 | 0001193125-25-045605 | EDGAR | — |
| 2024-12-20 | 0001193125-24-282407 | EDGAR | — |
| 2024-11-06 | 0001628280-24-045465 | EDGAR | — |
206 total filings indexed. 174 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001422142 |
| Ticker | WHWK |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.whitehawktx.com |
| Listed | 2021-08-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report